Rapha Capital Management, LLC
Venture capitalSurfside · Seed–Series A · 1 people tracked
Also known as Rapha Capital Bioventures · Rapha Capital PE Life Sciences
Investment thesis
Rapha Capital Management concentrates on discovering potentially disruptive biopharmaceutical companies among a broad field of less compelling opportunities. The firm aims to identify and nurture revolutionary ideas across medicine, healthcare and technology, seeking to recognize their value earlier than other investors.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from public directories
What they invest in
from 19 of 22 portfolio companiesBiotech ×15Healthtech ×8Longevity ×7Deep Tech ×5Medical Devices ×3New Materials ×2Advanced Manufacturing ×1AI & Machine Learning ×1
HQs:United States×14
Who they back
founder profiles across 15 portfolio companiesFounding team size:solo founder×112 founders×33 founders×1
Investments · 22 tracked
founders shown can be your intro pathBy year:2026 · 12020 · 12 dated
PartnerKevin M. Slawin· solo GP
Co-investorsAurum Venture PartnersBlue CollectiveExpaVU Venture PartnersFlucas Ventures
Biopharmaceutical company using computational biology to identify and develop novel peptide therapies, including AXT107 for retinal/eye diseases.
BiotechBethesda, US
Aleksander S. Popel, PhD(Executive Officer, Director)Jordan J. Green(Executive Officer, Director)Wendy Perrow(Executive Officer, Director)
PartnerKevin M. Slawin· solo GP
PartnerKevin M. Slawin· solo GP
Co-investorsAvoro Capital AdvisorsSolasta Ventures
PartnerKevin M. Slawin· solo GP
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
BiotechHouston, US
Ken Moseley(Executive Officer)Thomas J. Farrell(Executive Officer, Director)James F. Brown(Director)Annemarie Moseley(Executive Officer)Joseph Senesac(Executive Officer)Frank McGuyer(Director)
PartnerKevin M. Slawin· solo GP
Co-investorsForesite CapitalRA Capital
DELiver Therapeutics develops small molecule and peptide therapeutics using high-throughput DNA encoded library (DEL) drug screening to address challenging and previously "undruggable" targets in clinical medicine, with a focus on tyrosine kinase targets.
BiotechDeep TechHealthtechLongevityHouston, US
Kevin Slawin(Founder)in
PartnerKevin M. Slawin· solo GP
Ponce Aurora (deliverthera.com) develops small molecule kinase inhibitors discovered through DNA-encoded library (DEL) screening, including a multi-kinase inhibitor targeting ABL1-T315I and other tyrosine kinases for patients with Ph+ acute lymphocytic leukemia.
BiotechDeep TechLongevity
PartnerKevin M. Slawin· solo GP
Demeetra is a genome engineering company that develops precision gene-editing platforms — including Cas-CLOVER, Harbor-IN and Super piggyBac transposases and CleanCut CHO host cell lines — along with integrated cell line development and GMP manufacturing services.
BiotechDeep TechHealthtechLexington, US
Jack Crawford(CEO)
PartnerKevin M. Slawin· solo GP
BiotechHouston, US
Kevin Mark Slawin(Executive Officer, Director)in
BoardJerold Winograd(Director)Frank Bartlett McGuyer(Director)
PartnerKevin M. Slawin· solo GP
FIZE Medical develops an automated digital platform for fluid management in clinical settings, using real-time data to support clinical decision-making.
AI & Machine LearningDigital HealthHealthtechMedical Devices
Noam Levine(Founder)in
PartnerKevin M. Slawin· solo GP
BiotechAuburndale, US
Jim Hutchens(Executive Officer, Director)John Vacha(Executive Officer, Director)Ken Daignault(Director)Chris Bleck(Director)Robin Atlas(Director)
PartnerKevin M. Slawin· solo GP
K2bio is a contract research organization offering in vivo study design, execution, and analysis in an AAALAC-accredited vivarium, along with in vitro research and pharmacology services for biotech and pharmaceutical partners.
BiotechHealthtechHouston, US
Daniel Clark(Chief Financial Officer)Kieron Jones(Chief Executive Officer and Member of the Board of Directors)
BoardKevin Slawin(Member of the Board of Directors)inAndrew DeSomma(Member of the Board of Directors)Gerard Fleury(Member of the Board of Directors)Clifford J. Stocks(Member of the Board of Directors)
PartnerKevin M. Slawin· solo GP
NexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses.
BiotechMedical DevicesGaithersburg, US
Jonathan Schneck(Director)Alain Cappeluti(Executive Officer, Director)Kenneth Carter(Executive Officer, Director)
BoardJanis Naeve(Director)James Barrett(Director)
PartnerKevin M. Slawin· solo GP
Co-investorsPfizer Venture Investments
Numat develops metal-organic frameworks (MOFs) and manufactures them at industrial scale through an integrated campus with ISO 9001:2015 certified quality management.
Advanced ManufacturingCleantechDeep TechNew MaterialsIllinois, US
Ben Hernandez(Founder and Chief Executive Officer)Dr. Omar Farha(Founder and Chief Scientific Officer)
BoardT. Jay Collins(Director)Bill Kroll(Director)Luka Erceg(Director)Jeff Klunzinger(Director)
PartnerKevin M. Slawin· solo GP
Co-investorsGlobal BrainTEL Venture Capital, Inc.Universal Materials Incubator
Perseus SENOLYTIX is an oncology company developing MitoXcel oncopeptides, sequence-engineered peptides that target cancer cells through mitochondrial membrane potential rather than receptor- or kinase-based mechanisms.
BiotechDeep TechLongevity
PartnerKevin M. Slawin· solo GP
Phoenix SENOLYTIX is a longevity biotech developing controllable gene therapies that target the biological mechanisms of aging, based on its ApoptiCIDe-CE and ApoptiCIDe-RGT platforms and a proprietary cell-elimination switch triggered by a reformulated small molecule.
BiotechHealthtechLongevityHouston, US
PartnerKevin M. Slawin· solo GP
Ponce Aurora is a longevity company, affiliated with GEROTHERAPEUTIX, that develops cosmetics, beverages, and supplements designed to counteract aging and boost energy using licensed MitoXcel geropeptide technology.
BiotechLongevityWellness & Fitness
PartnerKevin M. Slawin· solo GP
Ponce Aurora is a longevity company developing cosmetics, beverages, and supplements that target aging-related cellular issues using proprietary geropeptide technology.
ConsumerHealthtechLongevity
PartnerKevin M. Slawin· solo GP
Poseida Therapeutics develops cell therapy candidates and related platform technologies for healthcare applications.
BiotechHealthtechSan Diego, US
Eric Ostertag(Executive Officer, Director)Mark Gergen(Executive Officer, Director)
BoardAdrian Howd(Director)David Hirsch(Director)
PartnerKevin M. Slawin· solo GP
Co-investorsAisling CapitalLongitude CapitalVivo Capital
PrintBio is a clinical- and commercial-stage biotechnology company developing 3D-bioprinting and material science technologies to create bioresorbable surgical mesh products, including its DynaFlex and DynaForm Programmable Surgical Mesh lines for soft tissue repair and reinforcement.
BiotechMedical DevicesNew Materials
PartnerKevin M. Slawin· solo GP
Senotherapeutix (d/b/a Gerotherapeutix) develops gerotherapeutics based on its MitoXcel geropeptide platform, which targets mitochondrial mechanisms of cellular aging to improve healthspan and extend lifespan.
BiotechHealthtechLongevityHouston, US
Dr. Slawin(Founder & Leader)
PartnerKevin M. Slawin· solo GP
Sightly, based in Silicon Valley, makes software for planning and analyzing video advertising campaigns.
FintechMedia & EntertainmentSilicon Valley, US
John Zdanowski(Executive Officer, Director)John McIntyre(Executive Officer, Director)Adam KatzJeff TagliabueRalph Mack
PartnerKevin M. Slawin· solo GP
Co-investors500 GlobalPlug and Play Ventures
Portfolio news
latest coverage across their companiesPoseida Therapeutics · ad-hoc-news.de · May 21, 2026
Eos SENOLYTIX · minichart.com.sg · May 15, 2026
Numat Technologies · trysignalbase.com · May 27, 2025
Frequently asked questions
- How many investments has Rapha Capital Management, LLC made?
- Rapha Capital Management, LLC has 22 tracked investments, including 1 dated in the last 24 months.
- What stage does Rapha Capital Management, LLC invest at?
- Rapha Capital Management, LLC invests at the Seed, Series A stages.
- What sectors does Rapha Capital Management, LLC focus on?
- Rapha Capital Management, LLC focuses on AgTech, Biotech, Healthtech, Medical Devices.
- Where is Rapha Capital Management, LLC located?
- Rapha Capital Management, LLC is headquartered in Surfside, US.
- Who does Rapha Capital Management, LLC co-invest with?
- Rapha Capital Management, LLC most often shares deals with Aisling Capital, Foresite Capital, Global Brain, among 14 tracked co-investors.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.
Granatus Ventures is a venture capital firm that backs startups worldwide leveraging Armenia's potential as an emerging technology hub.
Innovestor is a Finnish investment manager active in venture capital, real estate, and energy storage, and also provides corporate venturing services.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.